United States· US:0078-0937_09bbe9c5-f4a7-4140-8a74-809125cd7861
EGATEN
A triclabendazole product containing triclabendazole, registered in United States by Novartis Pharmaceuticals Corporation. The same ATC class is registered in 4 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Triclabendazole is registered in 4 of 19 countries.
Countries holding a registration under ATC P02BX04 (triclabendazole), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 3 of them publish a price we can compare per daily dose
Triclabendazole · ATC P02BX04
4 / 19 countries
- Franceprice
- Norwayprice
- United Kingdom
- United Statesprice
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- TRICLABENDAZOLE
- Manufacturer
- Novartis Pharmaceuticals Corporation
- Country
- United States (US)
- ATC code
- P02BX04
- ATC class
- Triclabendazole
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 1
- ndc110078-0937-91
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
278 interactions on record for triclabendazole.
Graded by severity as the source publishes them — 71 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Triclabendazole · interactions on record
278 records
- 71 severe
- 204 moderate
- 3 minor
Most severe, free to view
- PapaverineA03AD01severe
- CisaprideA03FA02severe
- DolasetronA04AA04severe
- QuinidineC01BA01severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Triclabendazole in 3 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FranceEGATEN 250 mg, comprimé sécableNOVARTIS PHARMA
- United KingdomEgaten 250mg tabletsImported (Switzerland)
- NorwayEgatenNovartis
Authorised across Europe · EMA
The same active substance is authorised in 1 EEA country. Names it is sold under:
- France · Egaten
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b73e64f7-1d34-453f-8c2a-f9bfccdd848b GET /v1/drugs/b73e64f7-1d34-453f-8c2a-f9bfccdd848b?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "ORAL",
"source": "ndc",
"strength": "250",
"substance": "TRICLABENDAZOLE",
"productndc": "0078-0937",
"dosage_form": "TABLET",
"dea_schedule": null,
"strength_unit": "mg/1",
"application_number": "NDA208711",
"marketing_category": "NDA"
}See everything about triclabendazole.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.